Investigational drug · Phase 3
SC0062
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for IgA Nephropathy (IgAN).
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 17, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "SC0062"
First trial start
2025
Feb 14, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SC0062", any sponsor or status.
Conditions studied
As listed on its trial records.
- IgA Nephropathy (IgAN)
Approved drugs for the same conditions: IgA nephropathy · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "SC0062" as an intervention, largest first.
- A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with ProteinuriaPivotal-lookingRecruiting
Biocity Biopharmaceutics Co., Ltd.Industry
NCT06819826 · 360 participants (planned) · Start Feb 14, 2025 · Primary completion Dec 31, 2026
Drug: SC0062 strength 10mg; Placebo matched to SC0062 · For: IgA Nephropathy (IgAN)
Sites: Guangzhou, China
- A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney DiseasePivotal-lookingStatus unknown
Biocity Biopharmaceutics Co., Ltd.Industry
NCT05687890 · 255 participants · Start May 23, 2023 · Primary completion Nov 30, 2024
Drug: Placebo of SC0062; SC0062 low dose and 2 more · For: Diabetic Kidney Disease; IgA Nephropathy
Sites: Hangzhou, China
University Medical Center GroningenAcademic, hospital or other
NCT06072326 · 36 participants (planned) · Start Jan 2027 · Primary completion Jan 2029
Drug: Dapagliflozin (Forxiga®); SC0062 strength 10mg and 1 more · For: Type 1 Diabetes Mellitus With Diabetic Nephropathy
Sites: Aarhus, Denmark; Copenhagen, Denmark; Herning, Denmark · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Unlocking the Potential of SC0062: A New Horizon in IgA Nephropathy Treatment?
Xiong J, Zhao J · J Am Soc Nephrol 2025
- Authors' Reply: Unlocking the Potential of SC0062: A New Horizon in IgA Nephropathy Treatment?
Chen J, Heerspink HJL · J Am Soc Nephrol 2025
- The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy: A Randomized Double-Blind Placebo-Controlled Clinical Trial.
Heerspink HJL, Du X, Xu Y, et al. · J Am Soc Nephrol 2025
- Efficacy and safety of endothelin A receptor antagonists in IgA nephropathy: a systematic review and meta-analysis.
Tian Z, Yang Y, Mei J, et al. · Clin Kidney J 2025
- Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin-A receptor antagonist.
Liu Y, Wang W, Qian H, et al. · Clin Transl Sci 2024
Also in development for IgA Nephropathy (IgAN)
- FUB523zigakibart, BION-1301Phase 36 trials
Novartis · IgA Nephropathy, Immunoglobulin A Nephropathy, IgA Nephropathy (IgAN)
- HSK39297Phase 35 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Haemoglobinuria (PNH)
- MY008211APhase 35 trials
Wuhan Createrna Science and Technology Co., Ltd · Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN)
- JADE101Phase 32 trials
Jade Biosciences, Inc. · IgA Nephropathy (IgAN), IgA Nephropathy
- HSK39297 200mgQDPhase 23 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Lupus Nephritis (LN)
- HSK39297 300mgQDPhase 22 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Lupus Nephritis (LN)
- SGB-9768Phase 22 trials
Suzhou Sanegene Bio Inc. · PNH - Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN), C3 Glomerulopathy
- SLN12140Phase 22 trials
Linno Pharmaceuticals, Inc. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria (PNH)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.